Satoshi Nishiwaki

List of Publications by Year
in descending order

48	501	759233 12	713466 21
papers	citations	h-index	g-index

48	48	48	720
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: a clue to refractory graft-versus-host disease. Blood, 2009, 114, 3113-3116.	1.4	63
2	Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABLâ€“positive acute lymphoblastic leukemia. Blood, 2014, 123, 2325-2332.	1.4	52
3	Allogeneic stem cell transplantation for adult Philadelphia chromosomeâ€“negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood, 2010, 116, 4368-4375.	1.4	47
4	Dexamethasone Palmitate Ameliorates Macrophages-Rich Graft-versus-Host Disease by Inhibiting Macrophage Functions. PLoS ONE, 2014, 9, e96252.	2.5	32
5	Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosomeâ€positive acute lymphoblastic leukemia. Cancer Science, 2019, 110, 3255-3266.	3.9	32
6	Optimization of Fludarabine + Melphalan Conditioning for Marrow Transplantation From Unrelated Donors for Patients with Hematopoietic Malignancies: A Prospective Dose-Finding Trial Using Modified Continual Reassessment Method.. Blood, 2009, 114, 2273-2273.	1.4	32
7	Impact of post-transplant imatinib administration on Philadelphia chromosome-positive acute lymphoblastic leukaemia. Anticancer Research, 2010, 30, 2415-8.	1.1	27
8	Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. International Journal of Hematology, 2012, 95, 428-433.	1.6	22
9	Dasatinib-based 2-step induction for adults with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood Advances, 2022, 6, 624-636.	5.2	19
10	Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosomeâ€“negative acute lymphoblastic leukemia in complete remission. Blood, 2011, 117, 3698-3699.	1.4	18
11	Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Biology of Blood and Marrow Transplantation, 2019, 25, 1597-1602.	2.0	16
12	Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells. Medicine (United States), 2018, 97, e0449.	1.0	15
13	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplantation, 2020, 55, 1317-1325.	2.4	14
14	Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. Stem Cells Translational Medicine, 2021, 10, 542-553.	3.3	13
15	A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics. Leukemia Research, 2016, 41, 21-26.	0.8	10
16	Gap between pediatric and adult approvals of molecular targeted drugs. Scientific Reports, 2020, 10, 17145.	3.3	9
17	Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia. International Journal of Hematology, 2021, 113, 832-839.	1.6	9
18	Allogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2012, 53, 550-556.	1.3	7

#	Article	IF	Citations
19	Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features. Frontiers in Oncology, 2020, 10, 586567.	2.8	7
20	Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2. Blood Advances, 2021, 5, 584-592.	5.2	7
21	COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective. Frontiers in Medicine, 2021, 8, 812370.	2.6	7
22	In vivo tracking of transplanted macrophages with near infrared fluorescent dye reveals temporal distribution and specific homing in the liver that can be perturbed by clodronate liposomes. PLoS ONE, 2020, 15, e0242488.	2.5	6
23	Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. Blood Advances, 2022, 6, 4558-4569.	5.2	5
24	Impact of the basal metabolic ratio in predicting early deaths after allogeneic stem cell transplantation. American Journal of Hematology, 2009, 84, 608-611.	4.1	4
25	Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e79-e85.	0.4	4
26	Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Medicine (United States), 2017, 96, e9568.	1.0	4
27	Availability of HLA-allele-matched unrelated donors: estimation from haplotype frequency in the Japanese population. Bone Marrow Transplantation, 2019, 54, 300-303.	2.4	4
28	Outcome of allogeneic bone marrow transplantation from unrelated donors for adult Philadelphia chromosome-negative acute lymphocytic leukemia in first complete-remission. International Journal of Hematology, 2010, 91, 419-425.	1.6	3
29	Pros and cons of legislation on allogeneic hematopoietic stem cell transplantation. Japanese Journal of Clinical Oncology, 2015, 45, 311-312.	1.3	2
30	Machine learning-aided risk stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia. Biomarker Research, 2021, 9, 13.	6.8	2
31	Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantationâ€"a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT. Bone Marrow Transplantation, 2021, 56, 2842-2848.	2.4	2
32	Complete nationwide survey on umbilical cord blood freezing bag breakage in Japan. Cytotherapy, 2014, 16, 1590-1594.	0.7	1
33	Cervical epidural hematoma in a healthy donor presenting stroke mimic symptoms: a rare adverse event following peripheral blood stem cell apheresis. Japanese Journal of Clinical Oncology, 2015, 45, 584-7.	1.3	1
34	Rules of providing cord blood for induced pluripotent stem cells for research. Cytotherapy, 2015, 17, 1008.	0.7	1
35	Different impact of BCRâ€ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Phâ€‰+â€‰ALL with minimal residual disease. American Journal of Hematology, 2019, 94, E301-E305.	4.1	1
36	Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan. Journal of Global Oncology, 2019, 5, 1-3.	0.5	1

#	Article	IF	Citations
37	A consideration for efficient unrelated hematopoietic stem cell source acquisitionâ€"from an experience of Japan. Bone Marrow Transplantation, 2020, 55, 657-660.	2.4	1
38	Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy. International Journal of Hematology, 2021, 114, 608-619.	1.6	1
39	The basal metabolic ratio: A sensitive index for predicting early death after allogeneic stem cell transplantation. American Journal of Hematology, 2010, 85, 830-830.	4.1	0
40	Provision of human immunodeficiency virus infection following cord blood transplantation. British Journal of Haematology, 2014, 166, 956-957.	2.5	0
41	Roles of volunteers and professionals in medical development--insights from the development of Allo-HSCT. Japanese Journal of Clinical Oncology, 2015, 45, 502-503.	1.3	0
42	The differential effect of disease status at allogeneic hematopoietic cell transplantation on outcomes in acute myeloid and lymphoblastic leukemia. Annals of Hematology, 2021, 100, 3017-3027.	1.8	0
43	Corticosteroid Therapy Does Not Increase Relapse Rate after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogeneous Leukemia and Myelodysplastic Syndrome Overt Leukemia.. Blood, 2007, 110, 1660-1660.	1.4	0
44	Impact of Posttransplant Imatinib Administration on Philadelphia-Chromosome Positive Acute Lymphocytic Leukemia. Blood, 2008, 112, 4416-4416.	1.4	0
45	Macrophage Infiltration of Skin Lesions Correlates to Prognosis of Gvhd; A Clue to Refractory Gvhd. Blood, 2008, 112, 1178-1178.	1.4	0
46	Impact of Macrophage Activation on Delayed Engraftment Following Allogeneic Hematopoietic Stem Cell Transplantation: Mac Ratio, a New Predictive Index. Blood, 2013, 122, 4527-4527.	1.4	0
47	Phase I Study of Cord Blood Transplantation with Intra-Bone Marrow Injection of Mesenchymal Stem Cells. Blood, 2019, 134, 2004-2004.	1.4	0
48	The Optimal Treatment Strategy for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission in the Era of High-Intensity Chemotherapy. Blood, 2019, 134, 4589-4589.	1.4	0